FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386592893> ?p ?o ?g. }

• W4386592893 endingPage "1359" @default.
• W4386592893 startingPage "1359" @default.
• W4386592893 abstract "Importance Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough. Objective To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough. Data Sources MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science from November 2014 to July 2023. Study Selection Two reviewers independently screened for parallel and crossover randomized clinical trials (RCTs) that compared, in patients with refractory or unexplained chronic cough, either gefapixant with placebo, or 2 or more doses of gefapixant with or without placebo. Data Extraction and Synthesis Two reviewers independently extracted data. A frequentist random-effects dose-response meta-analysis or pairwise meta-analysis was used for each outcome. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach was used to rate the certainty in whether patients would perceive the effects as important (greater than the minimal important difference [MID]) or small (less than the MID). Main Outcomes and Measures Cough frequency (measured using the VitaloJAK cough monitor; MID, 20%), cough severity (measured using the 100-mm visual analog scale [VAS]; higher score is worse; MID, 30 mm), cough-specific quality of life (measured using the Leicester Cough Questionnaire [LCQ]; score range, 3 [maximal impairment] to 21 [no impairment]; MID, 1.3 points), treatment-related adverse events, adverse events leading to discontinuation, and taste-related adverse events. Results Nine RCTs including 2980 patients were included in the primary analysis. Compared with placebo, gefapixant (45 mg twice daily) had small effects on awake cough frequency (17.6% reduction [95% CI, 10.6%-24.0%], moderate certainty), cough severity on the 100-mm VAS (mean difference, −6.2 mm [95% CI, −4.1 to −8.4]; high certainty), and cough-specific quality of life on the LCQ (mean difference, 1.0 points [95% CI, 0.7-1.4]; moderate certainty). Compared with placebo, gefapixant (45 mg twice daily) probably caused an important increase in treatment-related adverse events (32 more per 100 patients [95% CI, 13-64 more], moderate certainty) and taste-related adverse events (32 more per 100 patients [95% CI, 22-46 more], high certainty). High-certainty evidence suggests that gefapixant (15 mg twice daily) had small effects on taste-related adverse events (6 more per 100 patients [95% CI, 5-8 more]). Conclusions and Relevance Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events." @default.
• W4386592893 created "2023-09-12" @default.
• W4386592893 creator A5016751269 @default.
• W4386592893 creator A5026242254 @default.
• W4386592893 creator A5031717153 @default.
• W4386592893 creator A5031799727 @default.
• W4386592893 creator A5032461929 @default.
• W4386592893 creator A5048208596 @default.
• W4386592893 creator A5067464796 @default.
• W4386592893 creator A5079201163 @default.
• W4386592893 creator A5088117506 @default.
• W4386592893 date "2023-10-10" @default.
• W4386592893 modified "2023-10-17" @default.
• W4386592893 title "Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough" @default.
• W4386592893 cites W1541196807 @default.
• W4386592893 cites W1544610129 @default.
• W4386592893 cites W1605393132 @default.
• W4386592893 cites W1810814056 @default.
• W4386592893 cites W1977367528 @default.
• W4386592893 cites W1980632294 @default.
• W4386592893 cites W1994728074 @default.
• W4386592893 cites W2036147078 @default.
• W4386592893 cites W2038351470 @default.
• W4386592893 cites W2077290403 @default.
• W4386592893 cites W2086805009 @default.
• W4386592893 cites W2093536899 @default.
• W4386592893 cites W2106889389 @default.
• W4386592893 cites W2114691160 @default.
• W4386592893 cites W2127376430 @default.
• W4386592893 cites W2135806783 @default.
• W4386592893 cites W2136121047 @default.
• W4386592893 cites W2139344565 @default.
• W4386592893 cites W2141276486 @default.
• W4386592893 cites W2145550400 @default.
• W4386592893 cites W2157156095 @default.
• W4386592893 cites W2164981395 @default.
• W4386592893 cites W2165010366 @default.
• W4386592893 cites W2222678573 @default.
• W4386592893 cites W2235116583 @default.
• W4386592893 cites W2567362164 @default.
• W4386592893 cites W2753595517 @default.
• W4386592893 cites W2800621949 @default.
• W4386592893 cites W2924783581 @default.
• W4386592893 cites W2942307288 @default.
• W4386592893 cites W2970684805 @default.
• W4386592893 cites W2973217118 @default.
• W4386592893 cites W2978795816 @default.
• W4386592893 cites W2999874542 @default.
• W4386592893 cites W3008838890 @default.
• W4386592893 cites W3043859187 @default.
• W4386592893 cites W3118615836 @default.
• W4386592893 cites W3143901076 @default.
• W4386592893 cites W3155200986 @default.
• W4386592893 cites W3156206089 @default.
• W4386592893 cites W3206172917 @default.
• W4386592893 cites W3211195696 @default.
• W4386592893 cites W4213097104 @default.
• W4386592893 cites W4214937922 @default.
• W4386592893 cites W4236566513 @default.
• W4386592893 cites W4282919131 @default.
• W4386592893 cites W4283330095 @default.
• W4386592893 cites W4308532051 @default.
• W4386592893 cites W4311387242 @default.
• W4386592893 cites W4323307074 @default.
• W4386592893 cites W4361253321 @default.
• W4386592893 cites W4378953171 @default.
• W4386592893 doi "https://doi.org/10.1001/jama.2023.18035" @default.
• W4386592893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37694849" @default.
• W4386592893 hasPublicationYear "2023" @default.
• W4386592893 type Work @default.
• W4386592893 citedByCount "1" @default.
• W4386592893 crossrefType "journal-article" @default.
• W4386592893 hasAuthorship W4386592893A5016751269 @default.
• W4386592893 hasAuthorship W4386592893A5026242254 @default.
• W4386592893 hasAuthorship W4386592893A5031717153 @default.
• W4386592893 hasAuthorship W4386592893A5031799727 @default.
• W4386592893 hasAuthorship W4386592893A5032461929 @default.
• W4386592893 hasAuthorship W4386592893A5048208596 @default.
• W4386592893 hasAuthorship W4386592893A5067464796 @default.
• W4386592893 hasAuthorship W4386592893A5079201163 @default.
• W4386592893 hasAuthorship W4386592893A5088117506 @default.
• W4386592893 hasConcept C121332964 @default.
• W4386592893 hasConcept C126322002 @default.
• W4386592893 hasConcept C14184104 @default.
• W4386592893 hasConcept C142424586 @default.
• W4386592893 hasConcept C142724271 @default.
• W4386592893 hasConcept C168563851 @default.
• W4386592893 hasConcept C197934379 @default.
• W4386592893 hasConcept C204787440 @default.
• W4386592893 hasConcept C27081682 @default.
• W4386592893 hasConcept C2776042228 @default.
• W4386592893 hasConcept C2777707825 @default.
• W4386592893 hasConcept C2778375690 @default.
• W4386592893 hasConcept C2778715236 @default.
• W4386592893 hasConcept C42219234 @default.
• W4386592893 hasConcept C535046627 @default.
• W4386592893 hasConcept C71924100 @default.
• W4386592893 hasConcept C87355193 @default.

• next